Relay Therapeutics (RLAY) EV/EBIT: History & Chart

Relay Therapeutics, Inc.(RLAY)

Biotechnology · Cambridge, MA

$18.23-1.16 (-5.98%)

Delayed quote: Oct 6, 2026, 1:50 PM EDT

About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.

Cambridge, MA

202 employees

www.relaytx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sanjiv K. Patel

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Relay Therapeutics, Inc. (RLAY)	$3.99B	N/A	N/A	N/A	N/A
AbCellera Biologics Inc. (ABCL)vs ›	$4.02B	N/A	9.12x	14.02x	14.02x
ICU Medical, Inc. (ICUI)vs ›	$3.95B	45.28x	60.24x	289.81x	268.55x
LivaNova PLC (LIVN)vs ›	$4.14B	20.06x	18.41x	129.51x	140.01x
Regencell Bioscience Holdings Limited (RGC)vs ›	$3.79B	N/A	N/A	N/A	N/A
Edgewise Therapeutics, Inc. (EWTX)vs ›	$4.28B	N/A	N/A	N/A	N/A
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.39B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.41B	9.07x	11.90x	40.42x	37.42x
Heartflow, Inc. Common Stock (HTFL)vs ›	$4.43B	N/A	N/A	N/A	N/A
iRhythm Technologies, Inc. (IRTC)vs ›	$3.55B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Relay Therapeutics, Inc. (RLAY)

$3.99B

N/A

AbCellera Biologics Inc. (ABCL)vs ›

$4.02B

N/A

9.12x

14.02x